Patent Claims

1. Use of verapamil or verapamil derivatives for the inhibition of human tissue glucuronidase.

2. Use according to claim 1 characterised in that, as verapamil derivatives, there are used its R-enantiomer, metabolites of verapamil, gallopamil or chemically substituted derivatives of verapamil, gallopamil and its metabolites or its salts with pharmacologically compatible acids.

3. Use according to claim 1 or 2, characterised in that the R-enantiomers are used in pure form or, in comparison with the racemate, in enriched form.

4. Use according to claim 1 to 3, characterised in that the glucuronidase inhibitor is used, with suitable pharmacologically compatible adjuvants, orally or parenterally in normally liberating or controlled liberating form.

5. Use according to claim 1 to 4, characterised in that the glucuronidase inhibitor is used alone for the inhibition of β-glucuronidase in diseased tissue in order to prevent the progress of the disease, e.g. by inhibition of the tumour progression or the metastasis formation.

6. Use according to claim 1 to 4, characterised in that the glucuronidase inhibitor is used for the stabilisation of metabolically-formed glucuronide conjugates of side-effect-rich active materials in order to reduce their side effects or to introduce a detoxification.

7. Use according to claim 1 to 4, characterised in that the glucuronidase inhibitor is used combined with a glucuronide conjugate of an inflammation-inhibiting active material to be taken orally in order to protect this in the upper stomach-intestine tract against a cleavage and resorption and to activate in the deeper lying intestinal sections by cleavage for the intestinal local therapy.

8. Use according to claim 1 to 4 for the improvement of the tissue-specific therapy, characterised in that the glucuronidase inhibitor, in the case of combined use with a glucuronide prodrug, protects this against activation in healthy tissue in the case of maintenance of the activation in the target tissue.

9. Use according to claim 1 to 4 and 8, characterised in that, besides the glucuronidase inhibitor and the glucuronide prodrug, there is used combined beta-glucuronidase bound to tissue-specific substances (e.g. antibodies, proteins, liposomes) in order to increase the activation of the prodrug in the target tissue and to protect the healthy tissue against the activation.